Parkinson's Disease : Current and Future Therapeutics and Clinical Trials (Hardcover)

Part I. The Pharmacological Basis for Parkinson's Disease Treatment: 1. The pharmacological basis of Parkinson's disease therapy: an overview; 2. Anticholinergic agents in the management of Parkinson's disease; 3. Amantadine and antiglutamatergic drugs in the management of Parkinson's disease; 4. Monoamine oxidase inhibitors in the management of Parkinson's disease; 5. Oral dopamine agonists in the anagement of Parkinson's disease; 6. Subcutaneous, intranasal and transdermal dopamine agonists in the management of Parkinson's disease; 7. Oral and infusion levodopa therapy in the management of Parkinson's disease; 8. Catechol-O-methyltransferase inhibitors in the management of Parkinson's disease; 9. Experimental pharmacological agents in the management of Parkinson's disease; Part II. Management of Non-Motor Symptoms of Parkinson's Disease: 10. Management of autonomic dysfunction in Parkinson's disease; 11. Management of cognitive impairment in Parkinson's disease; 12. A neurobehavioralist approach to the management of cognitive impairment in Parkinson's disease; 13. Management of disease-related behavioral disturbances in Parkinson's disease; 14. Management of treatment-related behavioral disturbances in Parkinson's disease; 15. Management of sleep disorders in Parkinson's disease; 16. Management of pain and euromuscular complications in Parkinson's disease; Part III. Surgical Management of Parkinson's Disease: 17. Thalamotomy, pallidotomy and subthalamotomy in the management of Parkinson's disease; 18. Deep brain stimulation of the globus pallidus internus in the management of Parkinson's disease; 19. Deep brain stimulation of the subthalamic nucleus in the management of Parkinson's disease; 20. Deep brain stimulation of the thalamic ventral intermediate nucleus in the management of Parkinson's disease; 21. Emerging targets and other stimulation-related procedures in the management of Parkinson's disease; Part IV. Clinical Trials in Parkinson's Disease: Lessons, Controversies and Challenges: 22. Rating scales and clinical outcome measures in the evaluation of patients with Parkinson's disease; 23. Functional imaging markers as outcome measures in clinical trials for Parkinson's disease; 24. Cerebrospinal fluid and blood biomarkers as outcome measures in clinical trials for Parkinson's disease; 25. Lessons learned: neuroprotective trials in Parkinson's disease; 26. Lessons learned: symptomatic trials in early Parkinson's disease; 27. Controversy: GPi vs STN deep brain stimulation in the management of Parkinson's disease; 28. Controversy: ablative surgery vs deep brain stimulation in the management of Parkinson's disease; 29. Controversy: mid-stage vs advanced stage deep brain stimulation in the management of Parkinson's disease; 30. Lessons and challenges of trials for cognitive and behavioral complications of Parkinson's disease; 31. Lessons and challenges of trials for other non-motor complications of Parkinson's disease; 32. Lessons and challenges of trials involving ancillary therapies for the management of Parkinson's disease; Index.